CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Clene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.29+0.19 (+6.13%)
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Clene Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $129.00K | $56.00K | $119.00K | $129.00K | $194.00K | $257.00K | $237.00K | $316.00K | $316.00K | $478.00K | $498.00K | $242.00K | 65.5% | -33.5% |
| Royalty [Member] | $68.00K | $78.00K | $81.00K | $85.00K | $92.00K | $93.00K | $105.00K | $105.00K | $126.00K | $142.00K | $156.00K | $132.00K | 34.5% | -26.1% |
By region
From the segment and revenue-disaggregation notes of Clene's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.